CHM 10.0% 0.9¢ chimeric therapeutics limited

The company has plenty of cash now. Talk of a CR before any...

  1. 232 Posts.
    lightbulb Created with Sketch. 154
    The company has plenty of cash now. Talk of a CR before any trial results is just unrealistic.

    The directors literally introduced a new technology to imugene and the company received a 3m USD cash injection because of it. https://bioshares.com.au/blog/imugene-to-acquire-fourth-technology-platform?ListPageUrl=https://bioshares.com.au:443/premium-biotech-coverage/current-news

    As for the share price falling from ipo we'll ye, small company in a sector that's has been demolished. Ultimately these small biotechs either succeed and return many times your investment or they go to 0. To expect anything else is delusional. However I do think from here you can reasonably safely buy in, sell your principle out later on without seeing it through to the end and keep the ticket. At this stage though the results look promising and my current intention is to hold until product release or buyout.
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.